Although an underexplored area at present, targeted interventions to modulate clock activity for disease applications may spur drug development efforts for muscular dystrophy, particularly as combination therapy with currently available first-line treatments [64,65,66]. This evidence concerns the gene CLOCK and muscular dystrophy.